North America & Europe PEGylated Drugs Market 2018-2024 Report

North America and Europe PEGylated Drugs Market Size By Disease Indication (Cancer, Hepatitis, Multiple Sclerosis, Gastrointestinal Disorders), By Type (Monoclonal Antibodies, Colony Stimulating Factors, Interferons), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 – 2024

Report Content

Chapter 1.&nbsp; Methodology

1.1. Methodology

1.1.1.&nbsp; Methodology

1.1.2.&nbsp; Market definition

1.1.3.&nbsp; Forecast parameters

1.1.4.&nbsp; Data sources

1.1.4.1.&nbsp;&nbsp;&nbsp; Primary

1.1.4.2.&nbsp;&nbsp;&nbsp; Secondary

Chapter 2.&nbsp; Executive Summary

2.1. North America &amp; Europe PEGylated drugs industry 3600 synopsis, 2013 - 2024 (USD Million)

2.1.1.&nbsp; Business trends

2.1.2.&nbsp; Disease indication trends

2.1.3.&nbsp; Type trends

2.1.4.&nbsp; Regional trends

Chapter 3.&nbsp; North America &amp; Europe PEGylated Drugs Industry Insights

3.1. Industry segmentation

3.2. Industry impact forces

3.2.1.&nbsp; Growth drivers

3.2.1.1.&nbsp;&nbsp;&nbsp; Increasing prevalence of cancer in developed regions

3.2.1.2.&nbsp;&nbsp;&nbsp; Rising R&amp;D spending by biotechnology &amp; pharmaceutical companies in U.S. and Europe

3.2.1.3.&nbsp;&nbsp;&nbsp; Growing biologics sector in the developed economies

3.2.2.&nbsp; Industry pitfalls &amp; challenges

3.2.2.1.&nbsp;&nbsp;&nbsp; Drug recalls in the U.S. &amp; Europe

3.2.2.2.&nbsp;&nbsp;&nbsp; Adverse drug reactions

3.3. Growth potential analysis

3.3.1.&nbsp; By disease indication

3.3.2.&nbsp; By type

3.4. Regulatory landscape

3.4.1.&nbsp; U.S.

3.4.2.&nbsp; Europe

3.5. Porter&#39;s analysis

3.6. Pipeline analysis

3.7. Competitive landscape, 2017

3.7.1.&nbsp; Strategy dashboard

3.8. PESTEL analysis

Chapter 4.&nbsp; North America &amp; Europe PEGylated Drugs Market, By Disease Indication

4.1. North America &amp; Europe PEGylated drugs market share by disease indication, 2017 &amp; 2024&nbsp;

4.2. Cancer

4.2.1.&nbsp; Market estimates and forecast, by country, 2013 - 2024 (USD Million)

4.3. Hepatitis&nbsp;

4.3.1.&nbsp; Market estimates and forecast, by country, 2013 &ndash; 2024 (USD Million)

4.4. Multiple sclerosis

4.4.1.&nbsp; Market estimates and forecast, by country, 2013 &ndash; 2024 (USD Million)

4.5. Gastrointestinal disorders

4.5.1.&nbsp; Market estimates and forecast, by country, 2013 &ndash; 2024 (USD Million)

4.6. Others

4.6.1.&nbsp; Market estimates and forecast, by country, 2013 &ndash; 2024 (USD Million)

Chapter 5.&nbsp; North America &amp; Europe PEGylated Drugs, By Type

5.1. North America &amp; Europe PEGylated drugs market share by type, 2017 &amp; 2024&nbsp;

5.2. Monoclonal antibodies (mAbs)

5.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.3. Colony stimulating factors

5.3.1.&nbsp; Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.4. Interferons

5.4.1.&nbsp; Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.5. Others

5.5.1.&nbsp; Market estimates and forecast, by country, 2013 - 2024 (USD Million)

Chapter 6.&nbsp; North America &amp; Europe PEGylated Drugs Market, By Country

6.1. North America &amp; Europe PEGylated drugs market share by country, 2017 &amp; 2024&nbsp;

6.2. North America

6.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)

6.2.2.&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.2.3.&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.2.4.&nbsp; U.S.

6.2.4.1.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.2.4.2.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.2.5. Canada

6.2.5.1.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.2.5.2.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3. Europe

6.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)

6.3.2.&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.3.&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.4.&nbsp; Germany

6.3.4.1.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.4.2.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.5. France

6.3.5.1.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.5.2.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.6. UK

6.3.6.1.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.6.2.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.7. Spain

6.3.7.1.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.7.2.&nbsp;&nbsp;&nbsp; Market estimates and forecast, by type, 2013 - 2024 (USD Million)

Chapter 7.&nbsp; Company Profiles

7.1. Merck KGaA

7.1.1.&nbsp; Business overview

7.1.2.&nbsp; Financial data

7.1.3.&nbsp; Product landscape

7.1.4.&nbsp; Strategic outlook

7.1.5.&nbsp; SWOT analysis

7.2. Biogen Inc.

7.2.1.&nbsp; Business overview

7.2.2.&nbsp; Financial data

7.2.3.&nbsp; Product landscape

7.2.4.&nbsp; Strategic outlook

7.2.5.&nbsp; SWOT analysis

7.3. AstraZeneca

7.3.1.&nbsp; Business overview

7.3.2.&nbsp; Financial data

7.3.3.&nbsp; Product landscape

7.3.4.&nbsp; Strategic outlook

7.3.5.&nbsp; SWOT analysis

7.4. UCB

7.4.1.&nbsp; Business overview

7.4.2.&nbsp; Financial data

7.4.3.&nbsp; Product landscape

7.4.4.&nbsp; Strategic outlook

7.4.5.&nbsp; SWOT analysis

7.5. Amgen

7.5.1.&nbsp; Business overview

7.5.2.&nbsp; Financial data

7.5.3.&nbsp; Product landscape

7.5.4.&nbsp; Strategic outlook

7.5.5.&nbsp; SWOT analysis

7.6. Sigma Tau (Leadiant Biosciences)

7.6.1.&nbsp; Business overview

7.6.2.&nbsp; Financial data

7.6.3.&nbsp; Product landscape

7.6.4.&nbsp; Strategic outlook

7.6.5.&nbsp; SWOT analysis

7.7. Roche

7.7.1.&nbsp; Business overview

7.7.2.&nbsp; Financial data

7.7.3.&nbsp; Product landscape

7.7.4.&nbsp; Strategic outlook

7.7.5.&nbsp; SWOT analysis

7.8. Shire Group

7.8.1.&nbsp;&nbsp; Business overview

7.8.2.&nbsp;&nbsp; Financial data

7.8.3.&nbsp;&nbsp; Product landscape

7.8.4.&nbsp;&nbsp; Strategic outlook

7.8.5.&nbsp;&nbsp; SWOT analysis

7.9. Pfizer

7.9.1.&nbsp;&nbsp; Business overview

7.9.2.&nbsp;&nbsp; Financial data

7.9.3.&nbsp;&nbsp; Product landscape

7.9.4.&nbsp;&nbsp; Strategic outlook

7.9.5.&nbsp;&nbsp; SWOT analysis

7.10. Novo Nordisk

7.10.1. Business overview

7.10.2. Financial data

7.10.3. Product landscape

7.10.4. Strategic outlook

7.10.5. SWOT analysis

&nbsp;

&nbsp;

&nbsp;

North America and Europe PEGylated Drugs Market

Customize This Report

Industries

Information

Link

Global Headquarters